WO2000025765A2 - Wässrige arzneimittelformulierung zur oralen applikation - Google Patents
Wässrige arzneimittelformulierung zur oralen applikation Download PDFInfo
- Publication number
- WO2000025765A2 WO2000025765A2 PCT/EP1999/007891 EP9907891W WO0025765A2 WO 2000025765 A2 WO2000025765 A2 WO 2000025765A2 EP 9907891 W EP9907891 W EP 9907891W WO 0025765 A2 WO0025765 A2 WO 0025765A2
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- pharmaceutical composition
- aqueous pharmaceutical
- oral use
- salts
- use according
- Prior art date
Links
- 0 CN1C[C@]2NCC*[C@]2C1 Chemical compound CN1C[C@]2NCC*[C@]2C1 0.000 description 2
- FABPRXSRWADJSP-CHPOKUKFSA-N COc(c(N(C1CC1)C=C1C(O)=O)c(cc2F)C1=O)c2N1CC2NCCC[C@H]2C1 Chemical compound COc(c(N(C1CC1)C=C1C(O)=O)c(cc2F)C1=O)c2N1CC2NCCC[C@H]2C1 FABPRXSRWADJSP-CHPOKUKFSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
Definitions
- Aqueous pharmaceutical formulation for oral administration is provided.
- the present invention relates to an aqueous pharmaceutical composition for oral use, which comprises an active ingredient from the class of quinolone or naphthyridonecarboxylic acid antibiotics and at least one swellable polycarboxylic acid or a salt thereof, a process for their preparation and the use thereof for the production of a Drug.
- Quinolonecarboxylic acid antibiotics generally have a bitter taste, so that the direct oral application of this class of substances in the form of aqueous
- Formulations for therapy are not possible or acceptable.
- No. 5,152,986 describes weak cationic ion exchange resins which are loaded with quinolonecarboxylic acids for taste masking. These ion exchange resins are non-swellable polymer particles.
- the use of a formulation in humans, which contains such non-swellable polymer particles, has the disadvantage, however, that such formulations cause a sandy mouthfeel, which has a negative effect on patient acceptance and thus the adherence to therapy and consequently the success of therapy. This did not play a significant role in the invention of US 5,152,986, since it essentially focuses on taste-masked veterinary drug formulations (see, for example, column 6, lines 52-54).
- DE-A-39 15 347 discloses a process for producing a taste-masked complex drug from an ionic active ingredient
- Reaction of the active ingredient with a complementary ionogenic particulate polymer in which a moistened powdery mixture of the active ingredient and the polymer is prepared and dried.
- the polymer is used in particle form. A high water solubility of the polymers is not desirable.
- the active ingredients used are of the quinolone class. and naphthyridonecarboxylic acid antibiotics, both structurally and effectively different classes of drugs.
- the above-described essentially particulate ion exchange resin complex formulations basically have the problem that they cause a sandy mouthfeel in the patient, which leads to limited acceptance by the patient, less adherence to therapy and thus poorer treatment success. Furthermore, suspensions, including those which are produced using particulate ion exchange resin complexes, have a strong tendency to sediment, which can lead to inaccurate dosing even when shaken again by the patient, which in turn impairs the success of the therapy.
- U.S. 4,808,411 (Abbott) describes compositions of a complex of carbomers (acrylic acid polymers) and erythromycin and its derivatives, e.g.
- Clarythromycin for masking the taste of the active ingredient.
- These compounds are macrolide antibiotics whose chemical structure and mode of action are completely different from the class of quinolone and naphthyridonecarboxylic acid antibiotics.
- the complexes of erythromycin and derivatives with the carbomers apparently also have only a low affinity for one another, which means that the particles of the complex of erythromycin and its derivatives and the carbomer in suspension still taste very strongly bitter. It is therefore essential to coat these particles in order to achieve sufficient storage stability for the taste-masking effect (column 7, lines 60-68).
- the preparation of this complex requires the use of organic
- the carbomer / antibiotic complexes are preferably in dry form, particularly preferably in the form of particles of less than 420 ⁇ m
- Diameter used from which liquid suspensions for oral administration can be made can be made.
- the use of such comparatively coarse-particle systems often leads to sedimentation when used in aqueous suspensions, which, as described, can lead to inaccurate dosing.
- DE-A-40 13 110 (Hoechst) describes pharmaceutical preparations which contain a polyelectrolyte complex in microparticulate form and an active ingredient.
- Polyacids such as e.g. Xylan polysulfate, partially hydrophobically esterified xylan polysulfates etc. mentioned. They are produced by reacting the polyacids with the active ingredient, precipitating the polyelectrolyte complex and filtering. The particles obtained are ground to smaller sizes in the examples. Particulate polyelectrolyte complexes are always obtained.
- the task of this patent application was to influence the biodistribution, bioavailability or absorption of drugs by providing particulate systems with small diameters. The problem of taste masking of active pharmaceutical ingredients is not addressed there.
- US-A-5,695,784 describes a taste masked pharmaceutical composition comprising microencapsulated ciprofloxacin in its betaine form in an oily juice formulation.
- DE-A-39 30 733 relates to a specific process for the production of a complex drug from an ionogenic active ingredient by reacting the active ingredient with a complementary ionic particulate polymer to produce a formulation with a reduced intrinsic taste.
- European patent application EP-A-0 855 183 relates to a process for the production of flavor-masked pharmaceutical preparations of antibacterial quinolone derivatives, in which the quinolone derivative is mixed with at least one higher fatty acid and heated to a temperature of 30 to 40 ° C.
- the EP-A 0 855 183 was based on the task of achieving a taste lamination without the use of liquid carriers.
- the object of the present invention was to provide an aqueous pharmaceutical composition which comprises an active ingredient from the class of the quinolone or naphthyridonecarboxylic acid antibiotics for oral use, which
- - has sufficient taste masking, - is easy to manufacture (i.e., no additional process steps such as e.g.
- an aqueous pharmaceutical composition for oral use in humans which comprises an active ingredient from the class of quinolone or naphthyridone carboxylic acid antibiotics and at least one swellable polycarboxylic acid or a salt thereof.
- the aqueous pharmaceutical composition of the invention is a composition which essentially contains water as a solvent or
- Dispersant includes. This means that there are essentially no organic solvents. More specifically, the aqueous composition of the invention contains less than 1, preferably less than 0.5, particularly preferably less than 0.1% by weight of organic solvents. All detectable organic solvents are incorporated into the composition via residual solvents of the polycarboxylic acids used. brought. The addition of organic solvents during the preparation of the composition is not necessary.
- quinolone or naphthyridonecarboxylic acid antibiotics used in the aqueous composition of the invention are conveniently
- R 1 for C ] -C alkyl which is optionally substituted by 1 to 3 fluorine atoms, C 2 -C 3 alkenyl, C3-Cg-cycloalkyl, which is optionally substituted by 1 to 2 fluorine atoms, and phenyl, which is optionally substituted by 1 or 2 fluorine atoms is substituted,
- R 2 stands for hydroxy or -OR 3 , where R 3 stands for C r C 4 alkyl,
- R 4 represents hydrogen, amino, hydroxy, methoxy, halogen, methyl or vinyl
- R 5 represents hydrogen or halogen
- N atom represents a mono-, bi- or spirocyclic heterocycle bonded via the N atom, which optionally contains further nitrogen, oxygen or sulfur heteroatoms in all ring parts can and the Cj-C-alkyl optionally substituted by hydroxy, optionally substituted by 1 to 3 fluorine atoms; amino, aminomethyl, 1-aminoethyl or 2-aminopropyl optionally substituted by 1 or 2 C 1 -C 3 -alkyl groups on the nitrogen; Hydroxyimino or methoxyimino can be substituted, and which can optionally contain 1 or 2 double bonds,
- A represents N or CR 6 , wherein
- R ° represents hydrogen, halogen, methyl or methoxy, ethynyl, vinyl, hydroxy or cyano optionally substituted by 1 to 3 fluorine atoms,
- R 1 and R 6 together form a group of the formula -O-CH 2 -CH 2 -, which may optionally be substituted by a methyl group,
- EP-A-0 589 318 EP-A-0 357 047
- EP-A-0 588 166 GB-A-2 289 674
- WO 92/09 579 JP-03-007 283
- EP-A-0 241 206 EP-A-0 342 675
- WO 93/22 308 EP-A-0 550 903, EP-A-0 591 808 and EP-A-0 350 733.
- R 7 represents hydrogen, C r C 3 alkyl.
- quinolonecarboxylic acid of the following formula is particularly preferably used in the present invention:
- hydrochloride of the compound which carries the INN (International Non-Proprietary Name) moxifloxacin is very particularly preferably used.
- the compound shown carries the INN ciprofloxacin.
- the hydrochloride of the compound is particularly preferred according to the invention.
- the aqueous composition of the invention contains between 0.2% (m / V) and 50% (m / V) quinolonic and / or naphthyridonecarboxylic acids, the range from 1.0% (m / V) to 15% being particularly preferred. (m / V) (The unit m / V denotes mass per volume of the aqueous composition, ie 1 g of active ingredient per 100 ml of the composition corresponds to 1% (m / V)).
- the swellable polycarboxylic acids or their salts which are used according to the invention are natural, partially synthetic or synthetic polymers and salts and derivatives thereof which have at least 5 carboxyl functions in the molecule, which can also be present in deprotonated form as an anionic carboxylate group, and whose glass transition temperature changes on contact lowered with water.
- These swellable polycarboxylic acids or their salts are preferably selected from the group consisting of polyacrylic acids or derivatives thereof, pectins, Alginic acids, carboxymethyl starches, carboxymethyl celluloses and / or their salts.
- Polyacrylic acids and / or derivatives and / or salts thereof are particularly preferred.
- the polyacrylic acids are commercially available polyacrylic acids. like Carbopol ® ,
- Carbomer 910 (viscosity 1.0% 3000-7000 mPas according to NF 18), Carbopol 934 NF (viscosity 0.5% 30500-39400 mPas Brookfield), Carbopol 934P NF (viscosity 0.5% 29400-39400 mPas Brookfield) ), Carbopol 974P NF
- the test instructions used are specified.
- the viscosity of the polycarboxylic acids used according to the invention is preferably between 1000 mPas and 1 000 000 mPas (1% aqueous dispersion at pH 7.3-7.8, 24-26 ° C., 20 rpm,
- the polycarboxylic acids Carbopol 974P NF, Carbopol 971P NF and Noveon AA-1 USP are very particularly preferred, since they are obtained from ethyl acetate as a solvent and are therefore least toxicologically unsafe.
- the aqueous composition of the invention contains between 0.1% (w / v) and
- the molar ratio of the functional groups in the swellable polycarboxylic acid (carboxyl or carboxylate groups) to active substance molecules is in the range from 1:10 to 25: 1. Particularly favorable with regard to the factors influencing the use as a pharmaceutical, such as
- Viscosity, mouthfeel, pourability and taste, the preparation are ratios from 1: 1 to 12: 1.
- the aqueous pharmaceutical composition for oral use of the invention further contains at least one sweetener which is dissociable in water.
- a sweetener which can be dissociated in water means a sweetener which is at least partly present in ions in water at room temperature.
- Sweeteners are synthetic or naturally occurring compounds which have no or negligible caloric value in relation to the sweetness and have a higher sweetness than sucrose.
- the water-dissociable sweetener is preferably at least one sweetener selected from the group consisting of saccharin, salts of saccharin, acesulfame, salts of acesulfame, cyclamate, salts of cyclam ⁇ .ts, aspartame, salts of aspartame, thaumatin (talin ), Glycerrhetic acid or salts thereof and glycyrrhizin or salts thereof.
- saccharin and common salts of saccharin such as saccharin sodium, saccharin potassium, acesulfame, acesulfame potassium, cyclamate (cyclohexyl sulfamidic acid) or common salts (such as sodium cyclamate, potassium cyclamate), aspartame or salts with monovalent Cations (sodium or potassium salts), thaumatin (talin), glycerrhetic acid or salts with monovalent cations (sodium or potassium salts), glycyrrhizin or salts with monovalent cations (sodium or potassium salts).
- saccharin and common salts of saccharin such as saccharin sodium, saccharin potassium
- saccharin l, 2-benzisothiazol-3 (2H) -on-l, l-dioxide
- customary salts of saccharin such as saccharin sodium, saccharin potassium, acesulfame, acesulfame potassium, cyclamate (cyclohexylsulfamidic acid) are particularly preferred ) or common salts (such as sodium cyclamate, potassium cyclamate).
- the aqueous pharmaceutical formulation of the present invention suitably contains from 0.1% to 15% (m / V), preferably from 0.25% to 10% (m / V) and particularly preferably from 0.5% to 5% (m / V) V) the sweetener dissociable in water.
- the aqueous pharmaceutical formulation of the present invention optionally contains other conventional constituents for improving the taste, such as, for example, sugar, sugar alcohols or starches and their derivatives, examples of which are sucrose, glucose, glucose syrup, fructose, mannitol, sorbitol, xylitol, lactitol, starch, dextrin, maltodextrin , Glutamic acid or its salts (eg sodium glutamate).
- sugar, sugar alcohols or starches and their derivatives examples of which are sucrose, glucose, glucose syrup, fructose, mannitol, sorbitol, xylitol, lactitol, starch, dextrin, maltodextr
- Preparation contains 0-150% (m / V) of one or more of these components.
- aqueous pharmaceutical formulation of the present invention contains other customary substances for changing the color, taste or consistency of the preparation, such as e.g. Pigments, soluble dyes, flavorings or
- aroma substance is understood to mean a natural, nature-identical, partially synthetic or synthetic multicomponent mixture for influencing odor and / or taste, which is to be understood as one component), as well as neutral polymers or emulsifiers or one or more preservatives.
- the preparation appropriately contains up to eight of these components.
- basic components or bases for partial or complete neutralization of the polycarboxylic acid contained or for adjusting the pH in the preparation.
- basic components e.g. are used: alkali metal hydroxides, such as NaOH, KOH or organic amines.
- NaOH, KOH, NH 3 , ethanolamine or triethanolamine are particularly suitable.
- the necessary amounts of the added bases differ depending on the desired viscosity of the preparation and on the swellable polycarboxylic acid used.
- the molar ratio of active ingredient to basic component in the preparation is between 1: 0 (no base) and 1: 3, the range from being particularly preferred
- a physiologically justifiable pH is desirable for the use of the composition according to the invention.
- Preferred pH ranges are therefore pH 2 to 10; due to the good compatibility, pH values of pH 4 to 8 are very particularly preferred.
- a composition according to the invention is preferred which
- the preparation contains the single dose of the active ingredient in a conveniently applicable volume (expediently 1-50 ml, particularly preferably 2-15 ml).
- compositions according to the invention are bicoherent systems composed of a dispersion medium (preferably water and constituents dissolved therein) and the swellable polycarboxylic acids capable of gel formation and the active ingredient.
- transparent e.g. water-containing polyacrylate gel DAB 9
- cloudy e.g. vaginal gel pH 5 DAC 1986 / ⁇ RF, 10. Erg. 93
- opaque e.g. vaginal gel pH 5 DAC 1986 / ⁇ RF, 10. Erg. 93
- the size of the particles depends both on the degree of swelling and on the molecular weight and molecular structure of the polycarboxylic acid used. If one looks at the molecular structure of the systems, there exist within the Particles always covalent bonds. Physicochemical interactions are only involved in the formation of superordinate structures (gel framework).
- compositions of the invention appear to be particle-free.
- the viscosity of the compositions is always increased compared to the viscosity of the pure dispersion medium. Due to the internal structure of such gels, there is practically no sedimentation of the individual particles. Syneresis, which can be observed under certain circumstances and which describes the escape of dispersion medium from the gel framework, is a shrinking process of the gel framework
- the present invention also provides a new process for the preparation of the aqueous pharmaceutical composition for oral use of the invention which comprises:
- the active ingredient is first dissolved or suspended in water with stirring, then the swellable polycarboxylic acid is added in portions with stirring, optionally the water-dissociable sweetener (such as preferably sodium saccharin) is added to reduce the viscosity, and if necessary neutralizing or partially neutralizing the swellable polycarboxylic acid by adding bases with stirring, which leads to an increase in viscosity (gel formation with swelling of the swellable polycarboxylic acid). After the neutralization or partial neutralization, if appropriate, the further constituents are stirred in to improve the taste and the color or consistency of the preparation, as described above.
- the water-dissociable sweetener such as preferably sodium saccharin
- composition according to the invention stands out from the compositions of the prior art in that the formulation is a colloidal system which, in contrast to very fine to coarse-particulate
- compositions as required in the prior art can be dispensed with in the composition of the present invention, so that it can also be produced very inexpensively.
- the aqueous drug compositions of the invention have a reduced bitter taste compared to the pure active ingredients.
- the application of the bitter value according to DAB 10 to the formulation principle according to the invention cannot be used to quantify the improvement in taste, since the taste changes significantly when the preparation is diluted with water. The judgment of several test persons and undiluted preparations should therefore be used.
- the aqueous pharmaceutical composition for oral use of the invention is used in the manufacture of a medicament for combating bacterial infections in humans and animals.
- Magnetic stirrer does not stir. By adding 0.6 g of saccharin sodium, the viscosity is reduced to such an extent that stirring is possible. The remaining amount of Carbopol is stirred in portions. A stirring time is maintained until the suspension is free of larger agglomerates. Then stir in 12 g of powdered sugar and adjust the pH with sodium hydroxide solution (approx. 18 ml). The Viscosity can be adjusted by varying the amount of NaOH. Finally, the remaining 0.3 g of saccharin sodium are added.
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
Description
Claims
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU64736/99A AU6473699A (en) | 1998-10-30 | 1999-10-19 | Aqueous drug formulation for oral application |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE19850069.6 | 1998-10-30 | ||
DE19850069 | 1998-10-30 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2000025765A2 true WO2000025765A2 (de) | 2000-05-11 |
WO2000025765A3 WO2000025765A3 (de) | 2000-08-03 |
Family
ID=7886163
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/EP1999/007891 WO2000025765A2 (de) | 1998-10-30 | 1999-10-19 | Wässrige arzneimittelformulierung zur oralen applikation |
Country Status (3)
Country | Link |
---|---|
AU (1) | AU6473699A (de) |
HN (1) | HN1999000174A (de) |
WO (1) | WO2000025765A2 (de) |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2001010408A2 (de) * | 1999-08-06 | 2001-02-15 | Bayer Aktiengesellschaft | Wässrige arzneimittelformulierung von moxifloxacin oder salzen davon |
EP1411899A2 (de) * | 2001-08-01 | 2004-04-28 | Bristol-Myers Squibb Company | Zusammensetzung zur maskierung des geschmacks |
US8877945B2 (en) | 2009-05-15 | 2014-11-04 | Redx Pharma Limited | Redox drug derivatives |
US10561650B2 (en) | 2013-03-14 | 2020-02-18 | Christopher Brian Reid | Method for treating a protozoal infection |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5152986A (en) * | 1987-06-13 | 1992-10-06 | Bayer Aktiengesellschaft | Preparation and use of ion exchange resins loaded with quinolonecarboxylic acid derivatives |
WO1993017664A1 (en) * | 1992-03-02 | 1993-09-16 | Alcon Laboratories, Inc. | Combinations of cellulosic polymers and carboxy vinyl polymers and their use in pharmaceutical compositions |
EP0614659A2 (de) * | 1993-03-11 | 1994-09-14 | Taro Pharmaceutical Industries Limited | Arzneimittel in halbfester Form und eine Vorrichtung zu deren Verabreichung |
EP0689832A2 (de) * | 1994-06-29 | 1996-01-03 | Laboratorios S.A.L.V.A.T., S.A. | Antibiotische Zubereitung zur auralen Anwendung |
WO1999062498A1 (en) * | 1998-06-03 | 1999-12-09 | Taro Pharmaceutical Industries Ltd. | Spill resistant pharmaceutical compositions |
-
1999
- 1999-10-13 HN HN1999000174A patent/HN1999000174A/es unknown
- 1999-10-19 WO PCT/EP1999/007891 patent/WO2000025765A2/de active Application Filing
- 1999-10-19 AU AU64736/99A patent/AU6473699A/en not_active Abandoned
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5152986A (en) * | 1987-06-13 | 1992-10-06 | Bayer Aktiengesellschaft | Preparation and use of ion exchange resins loaded with quinolonecarboxylic acid derivatives |
WO1993017664A1 (en) * | 1992-03-02 | 1993-09-16 | Alcon Laboratories, Inc. | Combinations of cellulosic polymers and carboxy vinyl polymers and their use in pharmaceutical compositions |
EP0614659A2 (de) * | 1993-03-11 | 1994-09-14 | Taro Pharmaceutical Industries Limited | Arzneimittel in halbfester Form und eine Vorrichtung zu deren Verabreichung |
EP0689832A2 (de) * | 1994-06-29 | 1996-01-03 | Laboratorios S.A.L.V.A.T., S.A. | Antibiotische Zubereitung zur auralen Anwendung |
WO1999062498A1 (en) * | 1998-06-03 | 1999-12-09 | Taro Pharmaceutical Industries Ltd. | Spill resistant pharmaceutical compositions |
Cited By (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2001010408A2 (de) * | 1999-08-06 | 2001-02-15 | Bayer Aktiengesellschaft | Wässrige arzneimittelformulierung von moxifloxacin oder salzen davon |
WO2001010408A3 (de) * | 1999-08-06 | 2001-09-07 | Bayer Ag | Wässrige arzneimittelformulierung von moxifloxacin oder salzen davon |
US6916484B1 (en) | 1999-08-06 | 2005-07-12 | Bayer Aktiengesellschaft | Aqueous pharmaceutical composition containing moxifloxacin or salts thereof |
EP1411899A2 (de) * | 2001-08-01 | 2004-04-28 | Bristol-Myers Squibb Company | Zusammensetzung zur maskierung des geschmacks |
EP1411899A4 (de) * | 2001-08-01 | 2006-06-07 | Novartis Ag | Zusammensetzung zur maskierung des geschmacks |
US8877945B2 (en) | 2009-05-15 | 2014-11-04 | Redx Pharma Limited | Redox drug derivatives |
US10561650B2 (en) | 2013-03-14 | 2020-02-18 | Christopher Brian Reid | Method for treating a protozoal infection |
Also Published As
Publication number | Publication date |
---|---|
AU6473699A (en) | 2000-05-22 |
HN1999000174A (es) | 1999-10-13 |
WO2000025765A3 (de) | 2000-08-03 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DE3884461T2 (de) | Antibiotikum-Polymer Zusammensetzung. | |
DE60226012T2 (de) | Geschmacksmaskierte pharmazeutische formulierungen | |
DE69727386T2 (de) | Geschmacksmaskierte flüssige suspensionen | |
DE60128215T2 (de) | Beschichtungszusammensetzung zur geschmacksmaskierung | |
DE60108154T2 (de) | Pharmazeutische Zubereitungen enthaltend Clavulansäure | |
AU2003216399A1 (en) | Diphenhydramine tannate liquid and semi-solid compositions and methods of use | |
DE3124014A1 (de) | Aluminiumibuprofensuspensionen | |
DE2604044A1 (de) | Verfahren zur herstellung von praeparaten fuer die orale verabreichung | |
DE69935609T2 (de) | Formulierungen enthaltend cefuroxim-axetil | |
DE60309839T2 (de) | Feste lösung einer schwerwasserlöslichen substanz zur oralen verabreichung | |
DE69111574T2 (de) | Polycarbophil-Kalzium enthaltendes Arzneimittel. | |
US6861413B2 (en) | Stable non-dihydrate azithromycin oral suspensions | |
US20080125453A1 (en) | Phenylephrine tannate, pyrilamine tannate and dextromethorphan tannate salts in pharmaceutical compositions | |
DE60005012T2 (de) | Geschmacksmaskierte zubereitungen | |
EP1879555A2 (de) | Darreichungsform mit verbesserter freisetzung von cefuroximaxetil | |
US20040175418A1 (en) | Teste masking pharmaceutical composition | |
DE60017881T2 (de) | Trinkbare pharmazeutische suspension von ibuprofen | |
EP0373103B1 (de) | Flüssige orale Formulierung | |
WO2000025765A2 (de) | Wässrige arzneimittelformulierung zur oralen applikation | |
US20100048498A1 (en) | Stable non-dihydrate azithromycin oral suspensions | |
DE60217903T2 (de) | Flüssige pharmazeutische zusammensetzungen auf wasserbasis in suspensionsform zur oralen verabreichung von ibuprofen | |
EP2313083A1 (de) | Orale zusammensetzungen von clindamycin | |
EP0445158B1 (de) | Zubereitungen des oxipurinols und/oder seiner alkali- oder erdalkalisalze | |
US20200046762A1 (en) | Smectite suspension liquid composition and method for preparing same | |
DE60013583T2 (de) | Verfahren zur herstellung von arzneimitteln eines basischen hydrophoben wirkstoffs |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
ENP | Entry into the national phase |
Ref country code: AU Ref document number: 1999 64736 Kind code of ref document: A Format of ref document f/p: F |
|
AK | Designated states |
Kind code of ref document: A2 Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG |
|
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
AK | Designated states |
Kind code of ref document: A3 Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A3 Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG |
|
NENP | Non-entry into the national phase |
Ref country code: CA |
|
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
122 | Ep: pct application non-entry in european phase |